All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 22, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Interventions
DRUG

All-trans Retinoic Acid in combination with the KPD Regimen

"Regimen: 1 course of treatment for 28 days until disease progression or intolerable toxicity occurs~1. ATRA mg/m2/day in 2 oral doses for 3 days. The first dose of ATRA will be given in the morning, two days prior to carfilzomib administration.~ The last ATRA dose will be given in the evening on the day of carfilzomib administration.~2. Proteasome inhibitor: Carfilzomib 27mg/m2 2 consecutive days per week x 3 weeks (20mg/m2 on day 1 and day 2 of cycle 1);~3. Pomalidomide 4mg orally daily, d1-21;~4. Dexamethasone given orally only on days 1, 8, 15, and 22 of each cycle; ≤75 years: 40 mg/day; \>75 years: 20 mg/day."

Trial Locations (1)

361000

RECRUITING

Bing Xu, Xiamen

All Listed Sponsors
lead

The First Affiliated Hospital of Xiamen University

OTHER